Eli Lilly Sues Glenmark Over Cancer Drug ANDA

Law360, Los Angeles (January 23, 2014, 3:46 PM ET) -- Eli Lilly & Co. sued Glenmark Generics Inc. USA on Thursday in Indiana federal court, alleging the company's proposed generic version of its blockbuster cancer treatment drug Alimta infringes one of its patents.

Lilly claims that Glenmark's proposed generic Alimta infringes its U.S. Patent Number 7,772,209, which covers a method of administering pemetrexed disodium — Alimta's active ingredient — along with folic acid and vitamin B12.

Thursday's suit was the latest in a string of actions Lilly has filed to enforce the '209 patent since it...
To view the full article, register now.